A Study to Evaluate the Efficacy of BioCartilage® Micronized Cartilage Matrix in Microfracture Treatment of Osteochondral Defects
NCT ID: NCT03696394
Last Updated: 2019-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
15 participants
INTERVENTIONAL
2019-01-29
2023-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to assess whether adding BioCartilage® to microfracture treatment of osteochondral defects of the talus improves osteochondral healing as well as improving pain and function.
Efficacy will be assessed primarily by outcomes scores as measure by the Ankle Osteoarthritis Scale (AOS) at the baseline and at multiple post-op followup visits. Additional outcomes scores will also be administered to compare general health and foot function between the two groups at baseline and at multiple post-op followup visits. X-rays and MRI will be used to assess the osteochondral healing rate.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Effectiveness and Safety of an Implant in the Treatment of Osteoarthritis of the Great Toe
NCT00969969
An Evaluation Of Healthy Ankle Motion And Morphology
NCT03619382
Shoe Orthotics for Improvement of Biomechanics and Symptoms of Knee Osteoarthritis
NCT02234895
Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis
NCT02089880
Validation of Plantar Orthoses for Abnormal Plantar Arch Using a New Non-invasive Clinical Imaging System
NCT05163418
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I
Group I consists of 5 patients receiving a microfracture as per standard of care.
No interventions assigned to this group
Group II
Group II consists of 10 patients receiving a microfracture with BioCartilage®.
BioCartilage® Micronized Cartilage Matrix
BioCartilage® is a scaffold with Collagen Type II and cartilage matrix elements
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BioCartilage® Micronized Cartilage Matrix
BioCartilage® is a scaffold with Collagen Type II and cartilage matrix elements
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The subject has an isolated OCD with minimum dimensions of 0.07 cm2 (0.3 cm in diameter) and maximum dimensions of 2.25 cm2 as confirmed by a pre-op MRI.
3. The subject is independent, ambulatory, and can comply with all post-operative evaluations and visits.
4. The subject is at least nineteen (19) years of age and considered to be skeletally mature.
5. The subject has a combined bone and cartilage defect as determined by an MRI.
6. The patient has a stable ankle joint on history and has similar ligament stability with the opposite ankle.
7. The subject has less than 15 degrees of hindfoot valgus and 5 degrees of hindfoot varus.
8. The subject has a chronic defect not secondary to acute trauma within the last 6 months.
9. The patient (if having suffered a fracture) has no residual deformity of the tibia, fibula or syndesmosis.
10. The subject has a BMI of ≤ 40 kg/m².
11. The subject has exhausted non-operative treatment.
12. The subject has symptoms for less than a year.
13. Lesions on the subject must be contained.
Exclusion Criteria
2. The subject has an isolated OCD with dimensions greater than 2.0 cm2 on an MRI assessment.
3. The subject has an allergy to yeast-derived products.
4. The subject has implanted metallic devices (cardiac pacemakers, insulin pumps, and nerve stimulators), medically implanted clips, or other electronically, magnetically or mechanically activated implants that would contraindicate an MRI scan of the foot.
5. The subject has claustrophobia that would inhibit their ability to undergo an MRI scan of the foot.
6. The subject has tested positive or has been treated for a malignancy in the past, is suspected of having a malignancy, or is currently undergoing radiation or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed BioCartilage® site.
7. The subject is physically or mentally compromised (e.g., currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.), to the extent that the investigator judges the subject to be unable or unlikely to remain compliant to follow-up.
8. The subject is a prisoner, or is known or suspected to be transient.
9. The subject has documented evidence of a history (e.g. liver testing) of drug/alcohol abuse within the 12 months prior to screening for study entry.
10. The subject is pregnant or able to become pregnant but not practicing a medically-accepted form of birth control, and/or intending to become pregnant during this study period.
11. The subject currently has an acute infection in the area surrounding the surgical site.
12. The subject has a history of anaphylaxis or of multiple non-environmental allergies that may precipitate an anaphylactic reaction.
13. The subject's condition is bilateral and surgery is scheduled or to be scheduled over the course of this trial for both feet.
14. The subject requires a concomitant osteotomy of the tibia, fibula, or calcaneus for hindfoot deformity.
15. The subject requires a concomitant hindfoot fusion or has had a hindfoot fusion for hindfoot arthritis or deformity.
16. The subject is undergoing any concomitant surgery that may invalidate the outcome scores such as forefoot surgery or fusions, tendon transfers or ligament reconstructions. Heel cord lengthening is permitted.
17. The subject has an OCD of the tibia in isolation or in combination with the talar lesion
18. The subject is addicted to nicotine and on nicotine containing medication such as gum or a patch; or using nicotine containing substances such as cigarettes, cigars, pipe smoking or chewing tobacco.
19. The subject abuses cocaine or cocaine derivative drugs.
20. The subject has a known hypersensitivity to aprotinin.
21. The subject has diabetes with an HBA1c\> 7.5.
22. The subject is unable to give informed consent.
23. The subject is unable to comply with follow-up.
24. The subject is unable to communicate with the research team.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arthrex, Inc.
INDUSTRY
St. Paul's Hospital, Canada
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrea Veljkovic
Orthopaedic Surgeon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Paul's Hospital
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H18-00603
Identifier Type: OTHER
Identifier Source: secondary_id
ART - BioCartilage
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.